BioNTech's Leadership and Liquidity in Focus as Shareholders Face Crucial Vote

BioNTech's pivotal shareholder vote on May 15 seeks approval for major capital restructuring as founders step back and promising cancer trial data boosts shares.

A pivotal shareholder meeting on May 15 will define BioNTech’s future, as the company seeks approval for a major capital restructuring while navigating a profound leadership transition. The Mainz-based biotech firm is asking investors to authorize new capital equivalent to half of its current share capital, a move that could raise up to 129.5 million euros. This vote comes as founders Ugur Sahin and Özlem Türeci prepare to step back from their operational roles by year-end to launch a new, independent mRNA venture, with a full leadership transition expected by the end of 2026.

The strategic overhaul is backed by a formidable war chest. Despite a forecasted decline in annual revenue to around two billion euros, BioNTech’s liquidity remains robust, with cash reserves exceeding 17 billion euros. This financial cushion is critical as the company ramps up spending, with research and development expenses projected to climb to as much as 2.5 billion euros this year—surpassing expected income.

Investor sentiment has recently been buoyed by promising clinical data. Shares surged nearly ten percent last week, closing at 87.00 euros on Friday. This rally pushed the stock decisively above its 50-day moving average of 84.34 euros and to within roughly one percent of the closely watched 200-day line near 88 euros.

The optimism stems from progress in oncology, a central pillar of BioNTech’s post-pandemic strategy. In partnership with DualityBio, the drug candidate BNT323 (T-Pam) for HER2-positive endometrial cancer showed a response rate of nearly 50% in a Phase 2 trial. This marks a significant improvement over historical chemotherapy results of about 15% for this indication. The U.S. Food and Drug Administration has granted the therapy Fast Track designation, and BioNTech plans to file for regulatory approval later this year. A global Phase 3 trial is already underway to confirm these findings.

Analyst perspectives on the stock, however, are mixed. Bank of America raised its price target to $130, citing a potential T-Pam approval as foundational for building a commercial oncology infrastructure. In contrast, Leerink trimmed its target to $94, pointing to mixed data for the internally developed lung cancer candidate Gotistobart, seen as a key catalyst for 2024.

Before the annual meeting, the company will report first-quarter earnings on May 5, providing the first concrete look at this year’s revenue trajectory. The shareholder agenda also includes a proposed profit transfer agreement with subsidiary BioNTech Discovery GmbH, designed to make tax losses from the parent company’s previous year offsettable.

External challenges loom alongside internal changes. Potential U.S. import tariffs of 15% on pharmaceuticals, which could take effect by late July, threaten to complicate transatlantic production. The company’s broader ambition is to build a comprehensive oncology portfolio by 2030, a costly endeavor it is now financing from its pandemic-era reserves as vaccine revenue declines. The coming weeks will test investor confidence in this high-stakes transformation.